Play all audios:
Access through your institution Buy or subscribe Philanthropists, drugmakers and governments all agree: the world's poor are in dire need of new drugs for neglected diseases, but there
is not enough money available to develop innovative treatments. Now, a promising global treaty looks set to find a solution—and, unlike previous attempts to reach a similar agreement, this
one seems to have the backing of most major players involved in the drug development process. “A global R&D agreement used to be a crazy idea,” says James Love, an advocate for
affordable medicines and director of Knowledge Ecology International, a social justice nonprofit based in Washington, DC. “Now it looks more and more inevitable.” This is a preview of
subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only
$17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout
ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support Authors * Rebecca Hersher View author publications You can also
search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Hersher, R. Pharma backs latest attempt at a global health
R&D treaty. _Nat Med_ 18, 838 (2012). https://doi.org/10.1038/nm0612-838a Download citation * Published: 06 June 2012 * Issue Date: June 2012 * DOI: https://doi.org/10.1038/nm0612-838a
SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to
clipboard Provided by the Springer Nature SharedIt content-sharing initiative